Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus.
about
Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosusCyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosusCurrent and emerging treatment options in the management of lupusManagement of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future PerspectivesPredictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients.Apheresis for lupus erythematosus.Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents.Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus: a prospective cohort study.Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature.Apheresis for lupus erythematosus: state of the art.Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide.Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PETControlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.Central nervous system lupus: a clinical approach to therapy.A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus.Autoantibodies Affect Brain Density Reduction in Nonneuropsychiatric Systemic Lupus Erythematosus Patients.Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.Indications for plasma exchange in systemic lupus erythematosus in 2005.Emerging drug therapies for systemic lupus erythematosus.Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study.SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease.Update on emerging drug therapies for systemic lupus erythematosus.Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus.Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review.Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study.The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus.Clinical features and mortality in Chinese with lupus nephritis and neuropsychiatric lupus: A 124-patient study.Mycophenolate mofetil for lupus related myelopathy.Central nervous system manifestations after steroid pulse therapy in systemic lupus erythematosus.Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus.Clinical Factors Associated with Brain Volume Reduction in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations.Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy.Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers.
P2860
Q24200954-6D546B80-2AA4-4277-A19D-B26834F6D657Q24246092-EA65D5A9-B30F-4D2C-B998-593C3E4869CBQ26741266-80652ACC-C04C-4AD9-8116-1EF2BFA484D8Q26774815-E8FB3182-9998-4271-9B7B-F6905E59BD66Q30956012-159414E5-21D1-4D3D-A095-091AF0040EDCQ31145482-2AF94400-5A90-4B41-B825-890E2C2C34A7Q33328904-1B727583-BCBE-45AD-8C23-0017C4B57FE1Q33380516-BA3ACCA3-066E-4C8B-9B06-7589AAF58985Q33526071-E2962C1A-7175-45FE-95A8-3FE3A37FD450Q33832953-96C98533-3165-4E07-ACF9-857F654372B9Q34227026-BEE36F4E-A0DF-415E-B1A8-E6353B218680Q35299279-CAFBB003-F3E8-4E3F-A060-3F3A6FC26EEDQ35549279-4FD487B1-6BD6-4E71-8AAA-9A592ED97923Q35555433-97854E98-A4A2-4564-B3CF-1BAD8CD9B449Q35625240-08CE78FC-069A-4299-AB44-AB3DF9C47129Q35625245-F0B96E2F-BB7B-4962-AB33-BE72D1D74EA9Q35673044-93BAE93A-2C2C-4161-BE18-94C63784787CQ35918369-CB0A92AA-AC61-4B24-BC3C-1D51EBF4E5DEQ36334472-3E27AD36-3938-4CEF-8504-74E4A0CF21AAQ36634248-2516E02E-BAA1-48BB-A066-FEEC82486998Q36660675-9CCD0D53-6053-4F60-9FEB-68F38D73A625Q37226689-9B9D6917-53A0-49E2-A2B4-A85AFF30ECDEQ37227988-7458F048-6294-41D7-9AF3-CDE877C5B250Q37690745-51EA2B03-C3D3-464D-A516-972FDA15B326Q38099203-5F0CAEDD-56D0-4733-A0AC-257D22461E8BQ38101015-C3ED3513-A584-445B-A9FE-7D35476A1425Q40183545-0EBA374B-70FE-4A3B-9FBD-C1106BDC69F6Q40568409-7F0A7226-AF98-4392-90FF-CB62E04C8B46Q42019937-0A0534CA-4FA4-42F4-8FF0-93CD77819938Q42955806-CA605768-71A6-43A9-A58D-614BADCD4425Q44206388-5D68FF12-54CA-4F96-ADE6-62589BA2A103Q44782989-0E9960B9-7BFF-44D9-8D06-CE896E8E7335Q49562027-91C86C74-7B30-457D-92DA-965E0AB042D9Q53633371-DDBD049F-6277-4447-82D4-03AA975AA3A8Q54059237-9A71C246-2823-4E53-989D-7DE64972C31E
P2860
Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Role of intravenous cyclophosp ...... systemic lupus erythematosus.
@en
type
label
Role of intravenous cyclophosp ...... systemic lupus erythematosus.
@en
prefLabel
Role of intravenous cyclophosp ...... systemic lupus erythematosus.
@en
P2093
P1476
Role of intravenous cyclophosp ...... systemic lupus erythematosus.
@en
P2093
P356
10.1016/S0002-9343(99)80078-3
P407
P577
1995-01-01T00:00:00Z